SYK · Q2 2025 Earnings
BullishStryker Corporation
Reported July 31, 2025
30-second summary
Stryker grew revenue 11.1% to $6.02B with organic growth of 10.2%, and raised FY25 organic sales and EPS guidance despite a still-elevated $175M tariff hit. MedSurg & Neuro carried the quarter (+17.3%, with Vascular +52.3% on the Inari contribution), while Orthopaedics decelerated to +2% reported (+9.0% organic total; +10.7% ex-spinal reported, +9.7% ex-spinal constant currency). The print is clean: 120bps of gross margin expansion, 110bps of adjusted operating margin expansion in Q2, and management explicitly committing to another 100bps of adjusted operating margin lift for the full year.
Headline numbers
EPS
Q2 FY2025
$3.13
Revenue
Q2 FY2025
$6.02B
+11.1% YoY
Gross margin
Q2 FY2025
63.8%
Operating margin
Q2 FY2025
18.5%
Key financials
Q2 FY2025| Metric | Q2 FY2025 | YoY |
|---|---|---|
| Revenue | $6.02B | +11.1% |
| EPS | $3.13 | — |
| Gross margin | 63.8% | — |
| Operating margin | 18.5% | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Segment KPIs
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| MedSurg and Neurotechnology | $3.771B | +17.3% |
| Orthopaedics | $2.251B | +2.0% |
| Instruments | $0.768B | +10.0% |
| Endoscopy | $0.899B | +17.1% |
| Vascular | $0.498B | +52.3% |
| Neuro Cranial | $0.616B | +19.8% |
| MedSurg and Neurotechnology Organic Growth | 11.0% | — |
| Orthopaedics Organic Growth (ex-Spinal Implants) | 10.7% | — |
Other KPIs
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| United States | $4.554B | +12.5% |
| International | $1.468B | +6.8% |
| Adjusted Operating Income Margin | 25.7% | — |
| Adjusted Gross Profit Margin | 65.4% | — |
| Organic Net Sales Growth | 10.2% | — |
| Unit Volume Growth | 9.7% | — |
| Price Growth | 0.5% | — |
Management tone
Five distinct posture shifts on this print, all in the bullish direction. Management moved from "managing through headwinds" to declaring them offset: "We exited Q2 with strong momentum and are well positioned for the second half of the year. As a result, we are raising our full year 2025 outlook, which includes delivering another 100 basis points of adjusted operating margin expansion." The mid-year raise — coupled with explicit margin commitment — is unusual for a medical-device company carrying a $175M tariff weight and signals conviction in operating leverage. Notable nuance: the press release puts Q2 adjusted operating margin expansion at 110bps, while Preston on the call framed Q1 and Q2 as "100 basis points" each — the precise Q2 print is 110bps.
On tariffs specifically, the framing shifted from open-ended risk to a quantified, shrinking number: the FY estimate came down from approximately $200M to $175M, helped by the U.S.-China bilateral reduction partially offset by the EU framework moving to 15% from 10%. The risk has been bounded; management is no longer treating it as the swing variable.
Inari (NARI) tone shifted from integration risk to integration on track. Management acknowledged Q2 destocking, removal of quarterly incentives, replacement of sales leadership with Stryker personnel, and sales-rep attrition from new non-competes — then committed to double-digit pro forma growth for FY25. The most-difficult period is framed as behind them, with Q3/Q4 expected to step up.
International went from cautious framing to growth-driver framing: "We continue to view international markets as a big opportunity for future growth." South Korea, Canada and emerging markets were called out specifically, with second-half acceleration expected. The constraint is regulatory (EU MDR), not demand.
On the product pipeline, the language moved from "pending approvals" to "delivering now." Pangea hit its one-year launch anniversary with "robust" adoption, LifePak 35 received EU approval with a Q4 launch, and Mako crossed 2 million procedures with revision hip drawing positive surgeon feedback. Management called Stryker the "clear leader in orthopedic robotics" — an unusually direct competitive claim.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Larry Beagleson · Wells Fargo
What is driving confidence to raise organic growth and EPS guidance given market uncertainty? How much did supply issues impact growth and when will they be resolved? Separately, what is Stryker's strategy on remanufactured instruments for soft tissue robotics?
Kevin cited procedural strength (including July momentum), healthy order book, and strong capital demand. Supply issues are limited to medical division and will persist through year but medical has other strong products like LifePak 35 (approved in Europe, launching Q4). On remanufactured instruments, management declined to discuss pipeline products, saying they would announce if they enter that market.
Robbie Marcus · JP Morgan
What is driving impressive margin expansion to near pre-tariff/NRE guidance levels? Follow-up: How should we think about ASC expansion opportunity beyond orthopedics given heart ablation moving to ASC setting?
Preston attributed margin recovery to sustained pricing discipline, manufacturing efficiency improvements, procurement initiatives, better supply chain management, and OPEX discipline. Delivered consistent 100 bps operating margin improvement both Q1 and Q2. Kevin expressed confidence in continued ASC trend across specialties (cardiology, general surgery), noting it reduces healthcare costs and improves experience. Total ankle reimbursement increased $7,000, validating ASC model.
Ryan Zimmerman · BTIG
Tariff impact declined only $25M (from $200M to $175M) versus peers' larger reductions. Why? Follow-up: What is the greenfield opportunity for Mako robotics versus install-based penetration?
Preston explained tariff reduction driven by bilateral U.S.-China agreement benefit partially offset by EU framework increase to 15% (from 10%). Manufacturing footprint in Europe and lower China exposure vs. peers explains lesser benefit. Kevin stated universe of opportunity is 5,000 hospitals doing hips/knees with many operating rooms. Mako still in early innings; few hospitals have only one robot, most have multiple. Install-base number may be provided end-of-year alongside procedure percentage data.
Travis Deed · Bank of America
How did NARI grow this quarter amid D-Stock and sell-drop transitions? What drives confidence in double-digit 2025 growth and market rate return in 2026? Follow-up: Any impact from Medicaid exchange cuts on elective procedures and knee deceleration?
Kevin detailed destocking challenges (removed quarterly incentives, replaced sales leadership with Stryker personnel, implemented non-competes accepting some sales rep attrition). Underlying procedural demand was double-digit; stocking burn will continue. Expected double-digit full-year growth with most difficult period behind. Jason noted Medicaid is immaterial for Stryker procedures. Knee slowdown attributed to June seasonality; July started strong. No material knee market concerns.
David Roman · Goldman Sachs
How should we think about inorganic versus organic investment for international expansion, particularly given Pangea/Insignia launches in Europe? Reflections on SURF acquisition anniversary?
Kevin noted SURF acquisition extremely successful; hip business performed well internationally and will contribute to organic growth going forward. Biggest international opportunity is increasing penetration of existing portfolio products. MDR regulatory pathway has slowed European approvals (Pangea not approved until next year, Insignia still pending, only LifePak 35 approved). Launching in Japan before Europe in some cases. International growth acceleration expected in second half 2025.
What to watch into next quarter
Inari destocking burn-through: management committed to double-digit pro forma growth for FY25 and the "most difficult period behind us." Q3 Vascular organic ex-Inari-base and any commentary on sales-rep retention will reveal whether the destocking guide held.
Medical division supply resolution and LifePak 35 Q4 EU launch traction: supply constraints persist through year-end; watch whether Medical hits the committed double-digit H2 organic growth and whether LifePak 35 EU contribution is quantified on Q3.
Tariff estimate revisions: the $175M FY25 number replaced ~$200M this quarter. Any further EU framework changes or China rollback would move this number again — track whether the FY tariff figure holds or compresses further on the Q3 print.
Orthopaedics ex-spinal durability: +10.7% ex-spinal reported (+9.7% constant currency) this quarter is the cleaner signal masked by the spinal-implants divestiture. Watch whether this holds as comp difficulty rises, and whether Mako revision hip materially contributes.
Operating margin pacing: management committed to +100bps adjusted operating margin for FY25 after delivering +110bps in Q2. H2 has historically carried more leverage — watch whether they overshoot the 100bps commitment, which would signal further FY EPS guide raises.
Sources
- Stryker Corporation, Q2 2025 Earnings Press Release (SEC EX-99.1): https://www.sec.gov/Archives/edgar/data/310764/000031076425000103/sykex991earningsq22025.htm
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.